WELLCOME 311C MIGRAINE RESEARCH PROGRAM DIVESTMENT ORDERED BY FTC IN CONSENT AGREEMENT WITH GLAXO; MERGED COMPANY WILL HOLD 8.1% SHARE OF U.S. MARKET
Executive Summary
Glaxo must divest Wellcome's Phase II/III 331C90 migraine research program under a consent agreement with the Federal Trade Commission.